News and Announcements
Prescient Therapeutics Granted USPTO Allowances for Two PTX-200 Patents
- Published August 08, 2016 10:40AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
4th August 2016, ASX Announcement
Clinical-stage oncology company Prescient Therapeutics Limited (ASX:PTX) is pleased that the US Patent and Trademark Office (USPTO) has issued two notices of allowance under the PTX-200 patent families “Effective treatment of tumors and cancer with triciribine and related compounds” and “Compositions including triciribines and taxanes and methods of use thereof“.
The first allowance bears relevance to claims involving the intravenous dosing schedule of novel Akt inhibitor, PTX-200, including a method for identifying and treating patients with tumors in the pancreas, ovary or colon that have highly expressed Akt.
The second allowance has allowed claims bearing particular relevance to PTX’s ongoing breast cancer clinical trial, involving the use of PTX-200 with taxanes.
To view the full announcement, please click on the button below.